Broomfield, CO, United States of America

Donald Nicholas Hettinger

This inventor holds 10 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Neurocrine Biosciences, Inc.. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Donald Nicholas Hettinger. Retrieved from https://idiyas.com/inventor/donald-nicholas-hettinger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 51(Granted Patents)

Location History:

San Diego, CA (US) (2005 - 2021)
Broomfield, CO (US) (2014 - 2022)

Company Filing History:

10 out of 123

Neurocrine Biosciences, Inc.

patents

Years Active: 2005-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12686680 - Substituted pyrazolo[1,5-α]pyrimidines as CRF receptor antagonists (2026-07-21),

2. 11459305 - Processes for the preparation of uracil derivatives (2022-10-04),

3. 11040970 - VMAT2 inhibitor compounds and compositions thereof (2021-06-22),

4. 10494347 - Processes for the preparation of uracil derivatives (2019-12-03),

5. 9868706 - Processes for the preparation of uracil derivatives (2018-01-16),

6. 9382214 - Processes for the preparation of uracil derivatives (2016-07-05),

7. 8765948 - Processes for the preparation of uracil derivatives (2014-07-01),

8. 7459458 - Polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto (2008-12-02),

9. 7304069 - Hydrate of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5α]-pyrimidin-7-yl}phenyl)acetamide and processes and methods related thereto (2007-12-04),

10. 6903106 - Polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto (2005-06-07),

Title: **Donald Nicholas Hettinger – A Pioneer in Pharmaceutical Innovations**

Introduction

Donald Nicholas Hettinger is a remarkable inventor based in Broomfield, Colorado. With a portfolio of nine patents, Hettinger has made significant contributions to the field of pharmaceutical sciences. His innovations focus primarily on the development of important compounds that have potential therapeutic applications in treating neurological and psychiatric disorders.

Latest Patents

Among Hettinger's latest patents are groundbreaking processes for the preparation of uracil derivatives. This invention specifically relates to processes and intermediates for synthesizing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists, including their stereoisomers and pharmaceutically acceptable salts. Another notable patent is for VMAT2 inhibitor compounds and compositions, which includes a selection of compounds that demonstrate utility in treating various neurological and psychiatric diseases. This patent encompasses compounds defined by specific formulas, along with their salts, solvates, and hydrates, contributing significantly to the treatment landscape.

Career Highlights

Donald Nicholas Hettinger is associated with Neurocrine Biosciences, Inc., an esteemed organization in the pharmaceutical industry. His career at Neurocrine has been characterized by significant research and development initiatives aimed at advancing therapeutic options for patients in need.

Collaborations

Hettinger has worked alongside talented peers such as Donald J. Gallagher and Laszlo R. Treiber, collaborating on innovative projects that push the boundaries of current pharmaceutical practices. These collaborations have not only facilitated the advancement of their individual research but have also enhanced the collective expertise within Neurocrine.

Conclusion

Through his novel patents and collaborations, Donald Nicholas Hettinger exemplifies the spirit of innovation in the pharmaceutical sector. His work continues to pave the way for new treatment methodologies that could transform the care of those affected by neurological and psychiatric conditions. With a solid foundation of research and an unwavering commitment to medical advancements, Hettinger remains a prominent figure in the world of inventors and innovators.

Profile summary based on public USPTO records.